Fused amino pyridine as HSP90 inhibitors

A method of treating inflammatory diseases or immune system disorders in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (II):

• or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X2 and X5 are independently CH or N;
• R21-R23 are independently selected from the group consisting of hydrogen, halogen, amino, substituted amino, hydroxy, substituted hydroxyl, thiol, substituted thiol, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, CF3, NO2, CN, N3, substituted carbonyl, sulfonyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, or substituted cycloalkyl;
• R22 and R23 can be taken together from the carbon to which they are attached to form a saturated or unsaturated fused 5-8 membered cyclic ring optionally substituted with 0-3 heteroatom;
• M1 is absent, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl;
• M2 is absent, O, S, SO, SO2, N(R8), or C═O;
• M3 is absent, C═O, O, S, SO, SO2 or N(R8);
• M4 is hydrogen, halogen, CN, N3, hydroxy, substituted hydroxy, amino, substituted amino, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl;
• X is absent, O, S, S(O), S(O)2, N(R8), C(O), CF2, C(R8) or C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl in which one or more methylene can be interrupted or terminated by O, S, SO, SO2, N(R8), C(O);
• Y is independently hydrogen, halogen, NO2, CN, or lower alkyl;
• Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino;
• and,
• R8 is hydrogen, acyl, aliphatic or substituted aliphatic.

A method of treating inflammatory diseases or immune system disorders in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (III):

• or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X1-X5 are independently N or CR21, where R21 is independently selected from the group consisting of hydrogen, halogen, amino, substituted amino, hydroxy, substituted hydroxy, thiol, substituted thiol, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, CF3, NO2, CN, N3, substituted carbonyl, sulfonyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, or substituted cycloalkyl;
• M1 is absent, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl;
• M2 is absent, O, S, SO, SO2, N(R8), or C═O;
• M3 is absent, C|O, O, S, SO, SO2 or N(R8);
• M4 is hydrogen, halogen, CN, N3, hydroxy, substituted hydroxy, amino, substituted amino, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl;
• X is absent, O, S, S(O), S(O)2, N(R8), C(O), CF2, C(R8) or C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl in which one or more methylene can be interrupted or terminated by O, S, SO, SO2, N(R8), C(O);
• Y is independently hydrogen, halogen, NO2, CN, or lower alkyl;
• Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino;
• and,
• R8 is hydrogen, acyl, aliphatic or substituted aliphatic.

A method of treating inflammatory diseases or immune system disorders in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (IV):

• or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X2 and X5 are independently CH or N;
• R21 is independently selected from the group consisting of hydrogen, halogen, amino, substituted amino, hydroxy, substituted hydroxy, thiol, substituted thiol, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, CF3, NO2, CN, N3, substituted carbonyl, sulfonyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, or substituted cycloalkyl;
• Cy is a saturated or unsaturated fused 5-8 membered cyclic ring optionally substituted with 0-3 heteroatom;
• M1 is absent, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl;
• M2 is absent, O, S, SO, SO2, N(R8), or C═O;
• M3 is absent, C═O, O, S, SO, SO2 or N(R8);
• M4 is hydrogen, halogen, CN, N3, hydroxy, substituted hydroxy, amino, substituted amino, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl;
• X is absent, O, S, S(O), S(O)2, N(R8), C(O), CF2, C(R8) or C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl in which one or more methylene can be interrupted or terminated by O, S, SO, SO2, N(R8), C(O);
• Y is independently hydrogen, halogen, NO2, CN, or lower alkyl;
• Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino;
• and,
• R8 is hydrogen, acyl, aliphatic or substituted aliphatic.

A method of treating inflammatory diseases or immune system disorders in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (V):

• or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X2 and X5 are independently CH or N;
• R21 is independently selected from the group consisting of hydrogen, halogen, amino, substituted amino, hydroxy, substituted hydroxy, thiol, substituted thiol, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, CF3, NO2, CN, N3, substituted carbonyl, sulfonyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, or substituted cycloalkyl;
• Y1 and Y3 are independently O, S, N(R8), CH(R21);
• n is 1, 2, or 3;
• M1 is absent, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl;
• M2 is absent, O, S, SO, SO2, N(R8), or C═O;
• M3 is absent, C═O, O, S, SO, SO2 or N(R8);
• M4 is hydrogen, halogen, CN, N3, hydroxy, substituted hydroxy, amino, substituted amino, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl;
• R10 and R20 are independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl;
• X is absent, O, S, S(O), S(O)2, N(R8), C(O), CF2, C(R8) or C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl in which one or more methylene can be interrupted or terminated by O, S, SO, SO2, N(R8), C(O);
• Y is independently hydrogen, halogen, NO2, CN, or lower alkyl;
• Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino;
• and,
• R8 is hydrogen, acyl, aliphatic or substituted aliphatic.